製品・サービス別(機器、分析機器、迅速検査装置(RTD)、消耗品、薬物スクリーニング、分析機器、検査サービス)、検体種別(口腔液または唾液、呼気、毛髪、尿、その他の検体)、 エンドユーザー別(職場・学校、刑事司法制度・法執行機関、薬物検査ラボ、薬物治療センター、病院、個人ユーザー、疼痛管理センター、個人利用者、大学)、および地域別予測(2025年~2035年)Global Drug Screening Market Size Study and Forecast by Product and Services (Equipment, Analytical Instruments, Rapid Testing Devices (RTD), Consumables, Drug Screening, Analytical Instruments, and Laboratory Services), Sample Type (Oral Fluid or Saliva, Breath, Hair, Urine, and Other Samples), End User (Workplace and Schools, Criminal Justice Systems and Law Enforcement Agencies, Drug Testing Laboratories, Drug Treatment Centers, Hospitals, Personal Users, Pain Management Centers, Individual Users, and Colleges), and Regional Forecasts 20252035 Market Definition, Recent Developments & Industry Trends The global drug screening market encompasses products, technologies, and services used to detect the presence of illicit drugs, prescriptio... もっと見る
出版社
Bizwit Research & Consulting LLP
ビズウィットリサーチ&コンサルティング 出版年月
2026年3月24日
電子版価格
納期
3-5営業日以内
ページ数
285
言語
英語
英語原文をAI翻訳して掲載しています。
サマリーMarket Definition, Recent Developments & Industry TrendsThe global drug screening market encompasses products, technologies, and services used to detect the presence of illicit drugs, prescription medications, and controlled substances in biological samples. The market includes laboratory-based analytical instruments, rapid testing devices, consumables, and outsourced laboratory services utilized across workplace testing, criminal justice systems, healthcare settings, and personal use. Core stakeholders include diagnostic equipment manufacturers, laboratory service providers, healthcare institutions, law enforcement agencies, employers, and regulatory authorities responsible for substance control policies. In recent years, the market has undergone rapid transformation driven by heightened awareness of substance abuse, evolving regulatory mandates, and increasing adoption of point-of-care testing solutions. Technological advancements in immunoassay-based rapid testing, chromatography, and mass spectrometry have improved accuracy, sensitivity, and turnaround times. Additionally, rising opioid misuse, legalization of cannabis in several jurisdictions, and expanded workplace compliance requirements have reshaped demand patterns. Looking ahead to 2025-2035, digitization of testing workflows, integration of AI-enabled analytics, and decentralization toward home-based and on-site screening solutions are expected to significantly accelerate market expansion. Key Findings of the Report - Market Size (2024): USD 8.56 billion - Estimated Market Size (2035): USD 49.52 billion - CAGR (2025-2035): 17.30% - Leading Regional Market: North America - Leading Segment: Rapid Testing Devices (RTD) under Product and Services Market Determinants Rising Prevalence of Substance Abuse and Opioid Crisis The increasing incidence of drug misuse, particularly opioids and synthetic narcotics, is a primary driver of demand for drug screening solutions. Governments and employers are strengthening testing protocols to mitigate safety risks, reduce healthcare costs, and ensure regulatory compliance, thereby expanding market penetration. Workplace Safety Regulations and Compliance Mandates Stringent workplace safety standards across industries such as transportation, construction, and healthcare have institutionalized routine drug testing. Mandatory pre-employment, random, and post-incident screening programs generate consistent demand for rapid testing devices and laboratory services. Technological Advancements in Analytical Instruments Improvements in chromatography and mass spectrometry technologies have enhanced detection sensitivity and specificity, enabling laboratories to identify low-concentration substances and novel psychoactive drugs. These advancements support premium pricing and drive upgrades in established laboratories. Shift Toward Point-of-Care and Decentralized Testing The growing adoption of rapid testing devices allows on-site and near-patient drug detection with minimal infrastructure. This shift reduces turnaround times and operational costs, expanding testing accessibility in schools, treatment centers, and remote workplaces. Legal and Ethical Considerations Variability in drug legalization policies, particularly related to cannabis, creates complexity in compliance and interpretation of test results. Privacy concerns and regulatory inconsistencies may pose challenges to widespread implementation in certain regions. High Cost of Advanced Laboratory Infrastructure While rapid tests are cost-effective, confirmatory laboratory testing requires substantial investment in analytical instruments and skilled personnel. This capital intensity may limit expansion in emerging economies with constrained healthcare budgets. Opportunity Mapping Based on Market Trends Expansion of Home-Based and Personal Testing Kits Growing consumer awareness and demand for privacy are driving adoption of self-testing kits. Companies investing in user-friendly, reliable home-testing devices can capture new revenue streams beyond institutional buyers. Integration of Digital Reporting and Data Management Platforms Digitally connected testing systems that provide secure result reporting and analytics offer operational efficiency for employers and law enforcement agencies. Cloud-based compliance tracking systems represent a strategic growth avenue. Emerging Market Penetration Rising healthcare infrastructure investments and increasing substance abuse awareness in Asia Pacific and parts of LAMEA present untapped growth opportunities. Strategic distribution partnerships and localized manufacturing can facilitate market entry. Advanced Multi-Panel and Synthetic Drug Detection Solutions As new synthetic drugs emerge, demand for comprehensive multi-panel testing solutions is increasing. Investment in R&D for expanded detection panels positions companies to address evolving drug landscapes. Key Market Segments By Product and Services: - Equipment - Analytical Instruments - Rapid Testing Devices (RTD) - Consumables - Drug Screening - Analytical Instruments - Laboratory Services By Sample Type: - Oral Fluid or Saliva - Breath - Hair - Urine - Other Samples By End User: - Workplace and Schools - Criminal Justice Systems and Law Enforcement Agencies - Drug Testing Laboratories - Drug Treatment Centers - Hospitals - Personal Users - Pain Management Centers - Individual Users - Colleges Value-Creating Segments and Growth Pockets Rapid Testing Devices (RTD) currently represent a dominant and fast-expanding segment due to their portability, cost efficiency, and immediate result generation. While laboratory services maintain strong revenue contributions through confirmatory testing, decentralized rapid screening solutions are expected to accelerate at a higher growth rate. Among sample types, urine remains the most widely used due to established protocols and cost-effectiveness. However, oral fluid and hair testing are gaining traction owing to improved detection windows and non-invasive collection methods. In terms of end users, workplace and criminal justice systems dominate current demand, while personal users and colleges are emerging as high-growth segments driven by increased awareness and regulatory changes. Regional Market Assessment North America North America leads the drug screening market, supported by strict workplace regulations, high opioid misuse rates, and advanced laboratory infrastructure. The presence of major diagnostic companies and strong reimbursement frameworks further strengthens regional dominance. Europe Europe exhibits steady growth driven by structured regulatory oversight, public health initiatives, and workplace safety compliance. However, varying legalization policies across countries may influence testing frequency and market dynamics. Asia Pacific Asia Pacific is expected to witness the fastest growth during the forecast period. Increasing awareness of substance abuse, expanding healthcare infrastructure, and government-led anti-drug campaigns are key growth catalysts across emerging economies. LAMEA The LAMEA region presents moderate growth opportunities. Strengthening law enforcement initiatives in parts of Latin America and the Middle East support demand, though infrastructure limitations in certain African countries may restrict broader adoption. Recent Developments - January 2024: A leading diagnostics company launched an advanced multi-panel rapid drug testing device capable of detecting synthetic opioids. This innovation enhances on-site screening accuracy and addresses evolving drug abuse trends. - August 2023: Strategic partnership between a laboratory service provider and a workplace compliance platform to integrate digital reporting solutions. The collaboration streamlines regulatory documentation and employer compliance management. - May 2024: Expansion of a drug testing laboratory network in Asia Pacific to support growing demand from healthcare and law enforcement sectors. This move strengthens regional service accessibility and turnaround times. Critical Business Questions Addressed - What is the projected value creation potential of the drug screening market through 2035- The report analyzes demand drivers across institutional and personal testing segments to evaluate long-term revenue sustainability. - Which product categories are expected to deliver the highest growth rates- Segment-level analysis identifies rapid testing devices and advanced multi-panel solutions as high-growth areas. - How will regulatory changes influence market expansion- The study assesses the impact of evolving legalization policies and workplace mandates on testing frequency and adoption. - What regional strategies offer the strongest competitive advantage- Insights into regional regulatory environments and infrastructure maturity guide strategic expansion planning. - How can companies differentiate in a highly competitive landscape- The report evaluates innovation, digital integration, and cost efficiency as key competitive levers. Beyond the Forecast Drug screening is transitioning from a compliance-driven activity to a broader public health and safety instrument. Technology-enabled, decentralized testing models will redefine accessibility and operational efficiency. Sustained growth will depend on continuous innovation in detection capabilities, digital integration, and geographic expansion. Market participants that align regulatory compliance with scalable, user-centric solutions will capture long-term competitive advantage. 目次Table of ContentsChapter 1. Global Drug Screening Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Drug Screening Market Forces Analysis 3.1. Market Forces Shaping The Global Drug Screening Market (2024-2035) 3.2. Drivers 3.2.1. Rising Prevalence of Substance Abuse and Opioid Crisis 3.2.2. Workplace Safety Regulations and Compliance Mandates 3.2.3. Technological Advancements in Analytical Instruments 3.2.4. Shift Toward Point-of-Care and Decentralized Testing 3.3. Restraints 3.3.1. Legal and Ethical Considerations 3.3.2. High Cost of Advanced Laboratory Infrastructure 3.4. Opportunities 3.4.1. Expansion of Home-Based and Personal Testing Kits 3.4.2. Integration of Digital Reporting and Data Management Platforms Chapter 4. Global Drug Screening Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Drug Screening Market Size & Forecasts by Product and Services 2025-2035 6.1. Market Overview 6.2. Global Drug Screening Market Performance - Potential Analysis (2025) 6.3. Equipment 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Analytical Instruments 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Rapid Testing Devices (RTD) 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 6.6. Consumables 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.6.2. Market size analysis, by region, 2025-2035 6.7. Drug Screening 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.7.2. Market size analysis, by region, 2025-2035 6.8. Analytical Instruments 6.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.8.2. Market size analysis, by region, 2025-2035 6.9. Laboratory Services 6.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.9.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Drug Screening Market Size & Forecasts by Sample Type 2025-2035 7.1. Market Overview 7.2. Global Drug Screening Market Performance - Potential Analysis (2025) 7.3. Oral Fluid or Saliva 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Breath 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 7.5. Hair 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.5.2. Market size analysis, by region, 2025-2035 7.6. Urine 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.6.2. Market size analysis, by region, 2025-2035 7.7. Other Samples 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.7.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Drug Screening Market Size & Forecasts by End User 2025-2035 8.1. Market Overview 8.2. Global Drug Screening Market Performance - Potential Analysis (2025) 8.3. Workplace and Schools 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. Criminal Justice Systems and Law Enforcement Agencies 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 8.5. Drug Testing Laboratories 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.5.2. Market size analysis, by region, 2025-2035 8.6. Drug Treatment Centers 8.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.6.2. Market size analysis, by region, 2025-2035 8.7. Hospitals 8.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.7.2. Market size analysis, by region, 2025-2035 8.8. Personal Users 8.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.8.2. Market size analysis, by region, 2025-2035 8.9. Pain Management Centers 8.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.9.2. Market size analysis, by region, 2025-2035 8.10. Individual Users 8.10.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.10.2. Market size analysis, by region, 2025-2035 8.11. Colleges 8.11.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.11.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Drug Screening Market Size & Forecasts by Region 2025–2035 9.1. Growth Drug Screening Market, Regional Market Snapshot 9.2. Top Leading & Emerging Countries 9.3. North America Drug Screening Market 9.3.1. U.S. Drug Screening Market 9.3.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.3.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.3.1.3. End User breakdown size & forecasts, 2025-2035 9.3.2. Canada Drug Screening Market 9.3.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.3.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.3.2.3. End User breakdown size & forecasts, 2025-2035 9.4. Europe Drug Screening Market 9.4.1. UK Drug Screening Market 9.4.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.1.3. End User breakdown size & forecasts, 2025-2035 9.4.2. Germany Drug Screening Market 9.4.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.2.3. End User breakdown size & forecasts, 2025-2035 9.4.3. France Drug Screening Market 9.4.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.3.3. End User breakdown size & forecasts, 2025-2035 9.4.4. Spain Drug Screening Market 9.4.4.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.4.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.4.3. End User breakdown size & forecasts, 2025-2035 9.4.5. Italy Drug Screening Market 9.4.5.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.5.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.5.3. End User breakdown size & forecasts, 2025-2035 9.4.6. Rest of Europe Drug Screening Market 9.4.6.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.6.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.6.3. End User breakdown size & forecasts, 2025-2035 9.5. Asia Pacific Drug Screening Market 9.5.1. China Drug Screening Market 9.5.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.1.3. End User breakdown size & forecasts, 2025-2035 9.5.2. India Drug Screening Market 9.5.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.2.3. End User breakdown size & forecasts, 2025-2035 9.5.3. Japan Drug Screening Market 9.5.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.3.3. End User breakdown size & forecasts, 2025-2035 9.5.4. Australia Drug Screening Market 9.5.4.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.4.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.4.3. End User breakdown size & forecasts, 2025-2035 9.5.5. South Korea Drug Screening Market 9.5.5.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.5.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.5.3. End User breakdown size & forecasts, 2025-2035 9.5.6. Rest of APAC Drug Screening Market 9.5.6.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.6.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.6.3. End User breakdown size & forecasts, 2025-2035 9.6. Latin America Drug Screening Market 9.6.1. Brazil Drug Screening Market 9.6.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.6.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.6.1.3. End User breakdown size & forecasts, 2025-2035 9.6.2. Mexico Drug Screening Market 9.6.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.6.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.6.2.3. End User breakdown size & forecasts, 2025-2035 9.7. Middle East and Africa Drug Screening Market 9.7.1. UAE Drug Screening Market 9.7.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.1.3. End User breakdown size & forecasts, 2025-2035 9.7.2. Saudi Arabia (KSA) Drug Screening Market 9.7.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.2.3. End User breakdown size & forecasts, 2025-2035 9.7.3. South Africa Drug Screening Market 9.7.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.3.3. End User breakdown size & forecasts, 2025-2035 Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. LabCorp 10.2.1. Company Overview 10.2.2. Key Executives 10.2.3. Company Snapshot 10.2.4. Financial Performance (Subject to Data Availability) 10.2.5. Product/Services Port 10.2.6. Recent Development 10.2.7. Market Strategies 10.2.8. SWOT Analysis 10.3. Quest Diagnostics 10.4. Abbott 10.5. Thermo Fisher Scientific, Inc. 10.6. Alfa Scientific Designs, Inc. 10.7. OraSure Technologies, Inc. 10.8. Siemens 10.9. F. Hoffmann-La Roche Ltd 10.10. MPD Inc. 10.11. Shimadzu Corporation 10.12. Lifeloc Technologies, Inc. 図表リストList of TablesTable 1. Global Drug Screening Market, Report Scope Table 2. Global Drug Screening Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Drug Screening Market Estimates & Forecasts, 2024–2035 Table 9. Canada Drug Screening Market Estimates & Forecasts, 2024–2035 Table 10. UK Drug Screening Market Estimates & Forecasts, 2024–2035 Table 11. Germany Drug Screening Market Estimates & Forecasts, 2024–2035 Table 12. France Drug Screening Market Estimates & Forecasts, 2024–2035 Table 13. Spain Drug Screening Market Estimates & Forecasts, 2024–2035 Table 14. Italy Drug Screening Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Drug Screening Market Estimates & Forecasts, 2024–2035 Table 16. China Drug Screening Market Estimates & Forecasts, 2024–2035 Table 17. India Drug Screening Market Estimates & Forecasts, 2024–2035 Table 18. Japan Drug Screening Market Estimates & Forecasts, 2024–2035 Table 19. Australia Drug Screening Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Drug Screening Market Estimates & Forecasts, 2024–2035 ………….
SummaryMarket Definition, Recent Developments & Industry TrendsThe global drug screening market encompasses products, technologies, and services used to detect the presence of illicit drugs, prescription medications, and controlled substances in biological samples. The market includes laboratory-based analytical instruments, rapid testing devices, consumables, and outsourced laboratory services utilized across workplace testing, criminal justice systems, healthcare settings, and personal use. Core stakeholders include diagnostic equipment manufacturers, laboratory service providers, healthcare institutions, law enforcement agencies, employers, and regulatory authorities responsible for substance control policies. In recent years, the market has undergone rapid transformation driven by heightened awareness of substance abuse, evolving regulatory mandates, and increasing adoption of point-of-care testing solutions. Technological advancements in immunoassay-based rapid testing, chromatography, and mass spectrometry have improved accuracy, sensitivity, and turnaround times. Additionally, rising opioid misuse, legalization of cannabis in several jurisdictions, and expanded workplace compliance requirements have reshaped demand patterns. Looking ahead to 2025-2035, digitization of testing workflows, integration of AI-enabled analytics, and decentralization toward home-based and on-site screening solutions are expected to significantly accelerate market expansion. Key Findings of the Report - Market Size (2024): USD 8.56 billion - Estimated Market Size (2035): USD 49.52 billion - CAGR (2025-2035): 17.30% - Leading Regional Market: North America - Leading Segment: Rapid Testing Devices (RTD) under Product and Services Market Determinants Rising Prevalence of Substance Abuse and Opioid Crisis The increasing incidence of drug misuse, particularly opioids and synthetic narcotics, is a primary driver of demand for drug screening solutions. Governments and employers are strengthening testing protocols to mitigate safety risks, reduce healthcare costs, and ensure regulatory compliance, thereby expanding market penetration. Workplace Safety Regulations and Compliance Mandates Stringent workplace safety standards across industries such as transportation, construction, and healthcare have institutionalized routine drug testing. Mandatory pre-employment, random, and post-incident screening programs generate consistent demand for rapid testing devices and laboratory services. Technological Advancements in Analytical Instruments Improvements in chromatography and mass spectrometry technologies have enhanced detection sensitivity and specificity, enabling laboratories to identify low-concentration substances and novel psychoactive drugs. These advancements support premium pricing and drive upgrades in established laboratories. Shift Toward Point-of-Care and Decentralized Testing The growing adoption of rapid testing devices allows on-site and near-patient drug detection with minimal infrastructure. This shift reduces turnaround times and operational costs, expanding testing accessibility in schools, treatment centers, and remote workplaces. Legal and Ethical Considerations Variability in drug legalization policies, particularly related to cannabis, creates complexity in compliance and interpretation of test results. Privacy concerns and regulatory inconsistencies may pose challenges to widespread implementation in certain regions. High Cost of Advanced Laboratory Infrastructure While rapid tests are cost-effective, confirmatory laboratory testing requires substantial investment in analytical instruments and skilled personnel. This capital intensity may limit expansion in emerging economies with constrained healthcare budgets. Opportunity Mapping Based on Market Trends Expansion of Home-Based and Personal Testing Kits Growing consumer awareness and demand for privacy are driving adoption of self-testing kits. Companies investing in user-friendly, reliable home-testing devices can capture new revenue streams beyond institutional buyers. Integration of Digital Reporting and Data Management Platforms Digitally connected testing systems that provide secure result reporting and analytics offer operational efficiency for employers and law enforcement agencies. Cloud-based compliance tracking systems represent a strategic growth avenue. Emerging Market Penetration Rising healthcare infrastructure investments and increasing substance abuse awareness in Asia Pacific and parts of LAMEA present untapped growth opportunities. Strategic distribution partnerships and localized manufacturing can facilitate market entry. Advanced Multi-Panel and Synthetic Drug Detection Solutions As new synthetic drugs emerge, demand for comprehensive multi-panel testing solutions is increasing. Investment in R&D for expanded detection panels positions companies to address evolving drug landscapes. Key Market Segments By Product and Services: - Equipment - Analytical Instruments - Rapid Testing Devices (RTD) - Consumables - Drug Screening - Analytical Instruments - Laboratory Services By Sample Type: - Oral Fluid or Saliva - Breath - Hair - Urine - Other Samples By End User: - Workplace and Schools - Criminal Justice Systems and Law Enforcement Agencies - Drug Testing Laboratories - Drug Treatment Centers - Hospitals - Personal Users - Pain Management Centers - Individual Users - Colleges Value-Creating Segments and Growth Pockets Rapid Testing Devices (RTD) currently represent a dominant and fast-expanding segment due to their portability, cost efficiency, and immediate result generation. While laboratory services maintain strong revenue contributions through confirmatory testing, decentralized rapid screening solutions are expected to accelerate at a higher growth rate. Among sample types, urine remains the most widely used due to established protocols and cost-effectiveness. However, oral fluid and hair testing are gaining traction owing to improved detection windows and non-invasive collection methods. In terms of end users, workplace and criminal justice systems dominate current demand, while personal users and colleges are emerging as high-growth segments driven by increased awareness and regulatory changes. Regional Market Assessment North America North America leads the drug screening market, supported by strict workplace regulations, high opioid misuse rates, and advanced laboratory infrastructure. The presence of major diagnostic companies and strong reimbursement frameworks further strengthens regional dominance. Europe Europe exhibits steady growth driven by structured regulatory oversight, public health initiatives, and workplace safety compliance. However, varying legalization policies across countries may influence testing frequency and market dynamics. Asia Pacific Asia Pacific is expected to witness the fastest growth during the forecast period. Increasing awareness of substance abuse, expanding healthcare infrastructure, and government-led anti-drug campaigns are key growth catalysts across emerging economies. LAMEA The LAMEA region presents moderate growth opportunities. Strengthening law enforcement initiatives in parts of Latin America and the Middle East support demand, though infrastructure limitations in certain African countries may restrict broader adoption. Recent Developments - January 2024: A leading diagnostics company launched an advanced multi-panel rapid drug testing device capable of detecting synthetic opioids. This innovation enhances on-site screening accuracy and addresses evolving drug abuse trends. - August 2023: Strategic partnership between a laboratory service provider and a workplace compliance platform to integrate digital reporting solutions. The collaboration streamlines regulatory documentation and employer compliance management. - May 2024: Expansion of a drug testing laboratory network in Asia Pacific to support growing demand from healthcare and law enforcement sectors. This move strengthens regional service accessibility and turnaround times. Critical Business Questions Addressed - What is the projected value creation potential of the drug screening market through 2035- The report analyzes demand drivers across institutional and personal testing segments to evaluate long-term revenue sustainability. - Which product categories are expected to deliver the highest growth rates- Segment-level analysis identifies rapid testing devices and advanced multi-panel solutions as high-growth areas. - How will regulatory changes influence market expansion- The study assesses the impact of evolving legalization policies and workplace mandates on testing frequency and adoption. - What regional strategies offer the strongest competitive advantage- Insights into regional regulatory environments and infrastructure maturity guide strategic expansion planning. - How can companies differentiate in a highly competitive landscape- The report evaluates innovation, digital integration, and cost efficiency as key competitive levers. Beyond the Forecast Drug screening is transitioning from a compliance-driven activity to a broader public health and safety instrument. Technology-enabled, decentralized testing models will redefine accessibility and operational efficiency. Sustained growth will depend on continuous innovation in detection capabilities, digital integration, and geographic expansion. Market participants that align regulatory compliance with scalable, user-centric solutions will capture long-term competitive advantage. Table of ContentsTable of ContentsChapter 1. Global Drug Screening Market Report Scope & Methodology 1.1. Market Definition 1.2. Market Segmentation 1.3. Research Assumption 1.3.1. Inclusion & Exclusion 1.3.2. Limitations 1.4. Research Objective 1.5. Research Methodology 1.5.1. Forecast Model 1.5.2. Desk Research 1.5.3. Top Down and Bottom-Up Approach 1.6. Research Attributes 1.7. Years Considered for the Study Chapter 2. Executive Summary 2.1. Market Snapshot 2.2. Strategic Insights 2.3. Top Findings 2.4. CEO/CXO Standpoint 2.5. ESG Analysis Chapter 3. Global Drug Screening Market Forces Analysis 3.1. Market Forces Shaping The Global Drug Screening Market (2024-2035) 3.2. Drivers 3.2.1. Rising Prevalence of Substance Abuse and Opioid Crisis 3.2.2. Workplace Safety Regulations and Compliance Mandates 3.2.3. Technological Advancements in Analytical Instruments 3.2.4. Shift Toward Point-of-Care and Decentralized Testing 3.3. Restraints 3.3.1. Legal and Ethical Considerations 3.3.2. High Cost of Advanced Laboratory Infrastructure 3.4. Opportunities 3.4.1. Expansion of Home-Based and Personal Testing Kits 3.4.2. Integration of Digital Reporting and Data Management Platforms Chapter 4. Global Drug Screening Industry Analysis 4.1. Porter’s 5 Forces Model 4.2. Porter’s 5 Force Forecast Model (2024-2035) 4.3. PESTEL Analysis 4.4. Macroeconomic Industry Trends 4.4.1. Parent Market Trends 4.4.2. GDP Trends & Forecasts 4.5. Value Chain Analysis 4.6. Top Investment Trends & Forecasts 4.7. Top Winning Strategies (2025) 4.8. Market Share Analysis (2024-2025) 4.9. Pricing Analysis 4.10. Investment & Funding Scenario 4.11. Impact of Geopolitical & Trade Policy Volatility on the Market Chapter 5. AI Adoption Trends and Market Influence 5.1. AI Readiness Index 5.2. Key Emerging Technologies 5.3. Patent Analysis 5.4. Top Case Studies Chapter 6. Global Drug Screening Market Size & Forecasts by Product and Services 2025-2035 6.1. Market Overview 6.2. Global Drug Screening Market Performance - Potential Analysis (2025) 6.3. Equipment 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.3.2. Market size analysis, by region, 2025-2035 6.4. Analytical Instruments 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.4.2. Market size analysis, by region, 2025-2035 6.5. Rapid Testing Devices (RTD) 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.5.2. Market size analysis, by region, 2025-2035 6.6. Consumables 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.6.2. Market size analysis, by region, 2025-2035 6.7. Drug Screening 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.7.2. Market size analysis, by region, 2025-2035 6.8. Analytical Instruments 6.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.8.2. Market size analysis, by region, 2025-2035 6.9. Laboratory Services 6.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 6.9.2. Market size analysis, by region, 2025-2035 Chapter 7. Global Drug Screening Market Size & Forecasts by Sample Type 2025-2035 7.1. Market Overview 7.2. Global Drug Screening Market Performance - Potential Analysis (2025) 7.3. Oral Fluid or Saliva 7.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.3.2. Market size analysis, by region, 2025-2035 7.4. Breath 7.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.4.2. Market size analysis, by region, 2025-2035 7.5. Hair 7.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.5.2. Market size analysis, by region, 2025-2035 7.6. Urine 7.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.6.2. Market size analysis, by region, 2025-2035 7.7. Other Samples 7.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 7.7.2. Market size analysis, by region, 2025-2035 Chapter 8. Global Drug Screening Market Size & Forecasts by End User 2025-2035 8.1. Market Overview 8.2. Global Drug Screening Market Performance - Potential Analysis (2025) 8.3. Workplace and Schools 8.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.3.2. Market size analysis, by region, 2025-2035 8.4. Criminal Justice Systems and Law Enforcement Agencies 8.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.4.2. Market size analysis, by region, 2025-2035 8.5. Drug Testing Laboratories 8.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.5.2. Market size analysis, by region, 2025-2035 8.6. Drug Treatment Centers 8.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.6.2. Market size analysis, by region, 2025-2035 8.7. Hospitals 8.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.7.2. Market size analysis, by region, 2025-2035 8.8. Personal Users 8.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.8.2. Market size analysis, by region, 2025-2035 8.9. Pain Management Centers 8.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.9.2. Market size analysis, by region, 2025-2035 8.10. Individual Users 8.10.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.10.2. Market size analysis, by region, 2025-2035 8.11. Colleges 8.11.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035 8.11.2. Market size analysis, by region, 2025-2035 Chapter 9. Global Drug Screening Market Size & Forecasts by Region 2025–2035 9.1. Growth Drug Screening Market, Regional Market Snapshot 9.2. Top Leading & Emerging Countries 9.3. North America Drug Screening Market 9.3.1. U.S. Drug Screening Market 9.3.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.3.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.3.1.3. End User breakdown size & forecasts, 2025-2035 9.3.2. Canada Drug Screening Market 9.3.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.3.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.3.2.3. End User breakdown size & forecasts, 2025-2035 9.4. Europe Drug Screening Market 9.4.1. UK Drug Screening Market 9.4.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.1.3. End User breakdown size & forecasts, 2025-2035 9.4.2. Germany Drug Screening Market 9.4.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.2.3. End User breakdown size & forecasts, 2025-2035 9.4.3. France Drug Screening Market 9.4.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.3.3. End User breakdown size & forecasts, 2025-2035 9.4.4. Spain Drug Screening Market 9.4.4.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.4.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.4.3. End User breakdown size & forecasts, 2025-2035 9.4.5. Italy Drug Screening Market 9.4.5.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.5.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.5.3. End User breakdown size & forecasts, 2025-2035 9.4.6. Rest of Europe Drug Screening Market 9.4.6.1. Product and Services breakdown size & forecasts, 2025-2035 9.4.6.2. Sample Type breakdown size & forecasts, 2025-2035 9.4.6.3. End User breakdown size & forecasts, 2025-2035 9.5. Asia Pacific Drug Screening Market 9.5.1. China Drug Screening Market 9.5.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.1.3. End User breakdown size & forecasts, 2025-2035 9.5.2. India Drug Screening Market 9.5.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.2.3. End User breakdown size & forecasts, 2025-2035 9.5.3. Japan Drug Screening Market 9.5.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.3.3. End User breakdown size & forecasts, 2025-2035 9.5.4. Australia Drug Screening Market 9.5.4.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.4.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.4.3. End User breakdown size & forecasts, 2025-2035 9.5.5. South Korea Drug Screening Market 9.5.5.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.5.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.5.3. End User breakdown size & forecasts, 2025-2035 9.5.6. Rest of APAC Drug Screening Market 9.5.6.1. Product and Services breakdown size & forecasts, 2025-2035 9.5.6.2. Sample Type breakdown size & forecasts, 2025-2035 9.5.6.3. End User breakdown size & forecasts, 2025-2035 9.6. Latin America Drug Screening Market 9.6.1. Brazil Drug Screening Market 9.6.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.6.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.6.1.3. End User breakdown size & forecasts, 2025-2035 9.6.2. Mexico Drug Screening Market 9.6.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.6.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.6.2.3. End User breakdown size & forecasts, 2025-2035 9.7. Middle East and Africa Drug Screening Market 9.7.1. UAE Drug Screening Market 9.7.1.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.1.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.1.3. End User breakdown size & forecasts, 2025-2035 9.7.2. Saudi Arabia (KSA) Drug Screening Market 9.7.2.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.2.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.2.3. End User breakdown size & forecasts, 2025-2035 9.7.3. South Africa Drug Screening Market 9.7.3.1. Product and Services breakdown size & forecasts, 2025-2035 9.7.3.2. Sample Type breakdown size & forecasts, 2025-2035 9.7.3.3. End User breakdown size & forecasts, 2025-2035 Chapter 10. Competitive Intelligence 10.1. Top Market Strategies 10.2. LabCorp 10.2.1. Company Overview 10.2.2. Key Executives 10.2.3. Company Snapshot 10.2.4. Financial Performance (Subject to Data Availability) 10.2.5. Product/Services Port 10.2.6. Recent Development 10.2.7. Market Strategies 10.2.8. SWOT Analysis 10.3. Quest Diagnostics 10.4. Abbott 10.5. Thermo Fisher Scientific, Inc. 10.6. Alfa Scientific Designs, Inc. 10.7. OraSure Technologies, Inc. 10.8. Siemens 10.9. F. Hoffmann-La Roche Ltd 10.10. MPD Inc. 10.11. Shimadzu Corporation 10.12. Lifeloc Technologies, Inc. List of Tables/GraphsList of TablesTable 1. Global Drug Screening Market, Report Scope Table 2. Global Drug Screening Market Estimates & Forecasts By Region 2024–2035 Table 3. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 4. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 5. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 6. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 7. Global Drug Screening Market Estimates & Forecasts By Segment 2024–2035 Table 8. U.S. Drug Screening Market Estimates & Forecasts, 2024–2035 Table 9. Canada Drug Screening Market Estimates & Forecasts, 2024–2035 Table 10. UK Drug Screening Market Estimates & Forecasts, 2024–2035 Table 11. Germany Drug Screening Market Estimates & Forecasts, 2024–2035 Table 12. France Drug Screening Market Estimates & Forecasts, 2024–2035 Table 13. Spain Drug Screening Market Estimates & Forecasts, 2024–2035 Table 14. Italy Drug Screening Market Estimates & Forecasts, 2024–2035 Table 15. Rest Of Europe Drug Screening Market Estimates & Forecasts, 2024–2035 Table 16. China Drug Screening Market Estimates & Forecasts, 2024–2035 Table 17. India Drug Screening Market Estimates & Forecasts, 2024–2035 Table 18. Japan Drug Screening Market Estimates & Forecasts, 2024–2035 Table 19. Australia Drug Screening Market Estimates & Forecasts, 2024–2035 Table 20. South Korea Drug Screening Market Estimates & Forecasts, 2024–2035 ………….
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
Bizwit Research & Consulting LLP社の 医療・ライフサイエンス分野 での最新刊レポート
本レポートと同じKEY WORD(drug)の最新刊レポート
よくあるご質問Bizwit Research & Consulting LLP社はどのような調査会社ですか?Bizwit Research & Consulting (Bizwit Research & Consulting LLP)は世界の多様なマクロおよびマイクロ経済の動向を継続的に調査しています。 ... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|